Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novo Nordisk A/S (NVO) vs Unity Software Inc (U) Price & Performance

Novo Nordisk A/STrade
Unity Software IncTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Unity Software Inc — how do they compare? Novo Nordisk A/S trades at $37.96 (market cap $168.73B), while Unity Software Inc trades at $46.1 (market cap $20.00B). The key difference: Novo Nordisk A/S is far larger — about 8.4× Unity Software Inc's market cap, and Novo Nordisk A/S pays a 4.7% dividend while Unity Software Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Unity Software Inc for 50 Days on average.

NVOU
Market Cap
$168.73B$20.00B
Volume
13,531,26712,798,386
Sector
HealthTechnology
52-Week High
$63.98$49.47
52-Week Low
$35.29$17.13
Typical Hold Time
116 Days50 Days
Enterprise Value
$183.05B$19.88B
Dividend Yield
4.7%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $38.18, up 1.73% with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat estimates, with Q2 2026 EPS of $0.96 surpassing the $0.82 expectation. The company maintains robust cash flow generation of $119.1B from operations in 2025.

NVO presents compelling value with a 9.71 P/E ratio and 16.8% upside to the $44.67 consensus target. Key risks include FDA regulatory delays for hemophilia drug denecimig and intensifying competition from Eli Lilly in obesity treatments. The bullish analyst consensus (59% buy ratings) supports the growth outlook despite near-term headwinds.

Unity Software Inc

Unity Software (U) trades at $45.89, up 2.09% today, with strong technical momentum and bullish analyst sentiment. The stock shows improving fundamentals with revenue stabilizing around $1.8B-$2.0B and narrowing losses, though profitability remains negative. Recent catalysts include Meta VR Glasses support and positive sector momentum from Accenture's earnings. Technical indicators show the stock trading near resistance at $46 with overbought short-term RSI conditions.

Outlook remains cautiously optimistic with 82% analyst buy ratings and $45.27 consensus target. Key opportunities include VR/AR growth and advertising platform expansion, while risks center on persistent losses, high valuation multiples, and competitive pressures. The stock's current level near analyst targets suggests limited near-term upside without significant earnings improvement.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NVO
68% Buy32% Sell
Avg holding period · 116 Days
U

No sentiment data available yet.

Top news

Latest headlines on both assets

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO →

About Unity Software Inc

Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.

Read more on U →